GSK

With a $300 million investment in 23andMe, GSK pivots toward personalized medicine again, while the consumer genomics firm hitches its drug development ambitions to GSK.

Partnered Up

Pharmaceutical company GlaxoSmithKline and direct-to-consumer genetic testing company 23andMe have formed a drug discovery collaboration deal.

The companies will initially contribute equally to funding the collaboration and will share in future proceeds from drugs developed within the partnership.

The deal follows the release of a report that, among other things, urged support for genomics and other life sciences in the UK.

The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.

The firms will have exclusive access for a limited time to the data from the first 50,000 individuals with samples in the biobank to be sequenced.

The study seeks to identify biomarkers that can help personalize treatment for patients by identifying signs of rapid decline in kidney function.

It's Electric

GlaxoSmithKline and Verily Life Sciences form Galvani Bioelectronics.

Drug developers and genetic testing firms are contemplating how best to share variant classification data while protecting their commercial interests.

Five people have been indicted for stealing trade secrets from GlaxoSmithKline, the Wall Street Journal reports.

Pages

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.